Pregnancy amplifies diabetes management challenges at a critical time when blood sugar control directly impacts both mother and child health outcomes. Traditional monitoring methods often miss dangerous glucose swings that can lead to birth complications, preterm delivery, and long-term developmental issues for offspring. International diabetes experts have now issued comprehensive guidance on deploying advanced glucose monitoring and automated insulin delivery systems during pregnancy, marking a potential shift toward more precise maternal care.
The consensus establishes that continuous glucose monitoring provides measurable benefits for women with pre-existing type 1 diabetes, reducing pregnancy complications through real-time glucose tracking. Automated insulin delivery systems, which adjust insulin doses based on continuous readings, show emerging promise for type 1 diabetic pregnancies. However, the expert panel notes that optimal glucose thresholds for diagnosing gestational diabetes and target time-in-range goals for type 2 and gestational diabetes management require further determination through controlled trials.
This guidance arrives as diabetes technology rapidly advances beyond what pregnancy research has validated. Most existing studies focus on type 1 diabetes, leaving significant knowledge gaps for the growing population of women with type 2 or gestational diabetes. The recommendations represent expert consensus rather than definitive trial evidence, highlighting both the potential of these technologies and the urgent need for pregnancy-specific research. For the estimated 6-9% of pregnancies affected by diabetes, these technologies could transform outcomes, but implementation will require careful clinical validation and individualized protocols to ensure safety for both mother and developing child.